GHRP-2 — clinical evidence
Assessed outcomes with certainty ratings, contributing trials and the reasoning for each rating.
§3Clinical evidence
§3.1Growth hormone deficiency and growth-hormone secretagogue pharmacology
Anchor outcome. Peak stimulated growth hormone.
Effect as recorded. A peak growth hormone below 16 ng/mL after 100 µg intravenously supports severe adult growth-hormone deficiency in the approved Japanese diagnostic criteria; diagnostic threshold, not an efficacy estimate.[1,2]
Certainty. Moderate certainty The diagnostic evidence base is adequate and the compound holds a marketing authorisation for it. This does not extend to therapeutic use.
Contributing trials. GHRP2-JP-DIAGNOSTIC. Full structured abstracts are published for each.
Full evidence extract for growth hormone deficiency and growth-hormone secretagogue pharmacology · Indication assessment
§3.2Sarcopenia and lean-mass preservation during weight reduction
Anchor outcome. Change in appendicular lean mass by DXA.
Effect as recorded. No randomised human evidence identified for a body-composition outcome; —.[2,3]
Certainty. Very low certainty Approval for a diagnostic indication is not evidence of therapeutic benefit, and the Institute states this explicitly wherever a diagnostic approval exists.
Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.
Full evidence extract for sarcopenia and lean-mass preservation during weight reduction · Indication assessment
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology 1998;139(5):552–561. doi:10.1530/eje.0.1390552 · PMID 9849822
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism 2006;91(3):799–805. doi:10.1210/jc.2005-1536 · PMID 16352683
- Thevis M, Thomas A, Schänzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Review of Proteomics 2019;11(6):663–673. doi:10.1586/14789450.2014.965158
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.